Back

Beta-blocker therapy and all-cause mortality after percutaneous coronary intervention: a state-wide propensity score matched analysis stratified by left ventricular ejection fraction

31 August 2026 (08:39 - 08:51)
Organised by: Logo
Congress Presentation Part of: Secondary prevention strategies in coronary artery disease Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Pilar Ignacia Cataldo Miranda

Monash University, Melbourne (Australia)

4 More presentations in this session

Presentation thumbnail
Time-to-benefit of glucagon-like peptide-1 receptor agonists for cardiovascular protection in type 2 diabetes
Miss C. Chang (New Taipei, TW)
Abstract
Presentation thumbnail
SELECT in the light of FAST-MI. Potential population-based benefit of semaglutide 2.4mg/week on mortality, an extrapolation from the SELECT trial results to the FAST-MI registries.
Professor F. Schiele (Besancon, FR)
Abstract
Presentation thumbnail
Distinct phenotype of very early-onset coronary artery disease (≤35 years): baseline findings from a multicentre prospective cohort
Miss X. Ding (Beijing, CN)
Abstract
Presentation thumbnail
Beyond the genome: the dominant role of biological age over polygenic risk in post-PCI mortality prediction.
Miss M. Liu (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Secondary prevention strategies in coronary artery disease

The Event

Event poster

ESC Congress 2026

31 August 2026 08:39 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic impact of beta-blockers in AMI patients with mid-range left ventricular ejection fraction
21 May 2023
thumbnail
Congress Presentation
Effects of percutaneous coronary intervention on improvement of left ventricular ejection fraction among chronic coronary syndrome patients with left ventricular systolic dysfunction
25 August 2023
thumbnail
Congress Presentation
Impact of morphine use on mortality in STEMI patients treated with primary PCI - preliminary data from a new registry
15 April 2021
thumbnail
Congress Presentation
Evaluation of the mortality rate in patients with hfref with LVEF less than 25% in a specialized outpatient clinic
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources